Acute and one-year clinical outcomes following implantation of bioresorbable vascular scaffolds: the ABSORB UK Registry

EuroIntervention 2018;13:1554-1560 published online November 2017. DOI: 10.4244/EIJ-D-17-00886

Andreas Baumbach
Andreas Baumbach1,2*, MD; Azfar Zaman3, MD; Nick E.J. West4, MD; Peter O’Kane5, MD; Mohaned Egred3, MD; Thomas Johnson2, MD; Stephen Wheatcroft6, MD; Ruth Bowles2, BSc; Adam de Belder7, MD; Georgios Bouras8, MD; Alexandra Lansky1,8, MD; Jonathan Hill9, MD; Anthony Mathur1, MD; Mark A. de Belder10, MD; Adrian P. Banning11, MD; for the ABSORB UK investigators
1. Barts Heart Centre, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom; 2. Bristol Heart Institute, University Hospitals Bristol, Bristol, United Kingdom; 3. Department of Cardiology, Fre

Aims: The aim of this registry was to monitor practice patterns and outcomes in patients treated with Absorb bioresorbable vascular scaffolds (BVS) during the early phase of usage in the

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

bioresorbable scaffoldsclinical researchstent thrombosis
Stents and scaffolds
Read next article
Four-year follow-up of the randomised comparison between an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II Trial)

Latest news